Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS)

Key Points

• Unusually high put activity: Traders bought 48,840 put options on GOSS on Thursday — about a 414% increase versus typical put volume, indicating notable bearish bets or hedging.
• Analyst view mixed but consensus positive: Six analysts rate Gossamer Bio a Buy and one a Sell, producing a consensus of "Moderate Buy" with an average target price of $8.60 despite recent divergent ratings.
• Heavy institutional ownership and recent buying: Institutional investors own 81.23% of Gossamer Bio, and large holders such as Vanguard and State Street materially increased their positions in recent quarters.

Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 48,840 put options on the stock. This represents an increase of approximately 414% compared to the typical volume of 9,503 put options.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GOSS. Weiss Ratings reiterated a "sell (d-)" rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Barclays assumed coverage on shares of Gossamer Bio in a research report on Tuesday, January 27th. They issued an "overweight" rating and a $9.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Gossamer Bio from a "hold" rating to a "sell" rating in a report on Friday, January 23rd. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Gossamer Bio presently has a consensus rating of "Moderate Buy" and an average target price of $8.60.

Institutional Investors Weigh In On Gossamer Bio

Several large investors have recently made changes to their positions in GOSS. Vanguard Group Inc. lifted its position in Gossamer Bio by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company's stock valued at $31,586,000 after acquiring an additional 598,981 shares in the last quarter. State Street Corp raised its stake in shares of Gossamer Bio by 139.7% in the 4th quarter. State Street Corp now owns 9,310,969 shares of the company's stock valued at $28,864,000 after purchasing an additional 5,427,302 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Gossamer Bio by 12.4% in the second quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company's stock valued at $8,786,000 after purchasing an additional 787,909 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Gossamer Bio by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company's stock worth $15,109,000 after buying an additional 183,183 shares during the period. Finally, Corient Private Wealth LLC grew its holdings in shares of Gossamer Bio by 8.9% during the second quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company's stock worth $4,543,000 after buying an additional 302,200 shares in the last quarter. Institutional investors own 81.23% of the company's stock.

Gossamer Bio Stock Performance

Shares of GOSS opened at $2.17 on Thursday. The stock has a 50 day simple moving average of $2.79 and a 200 day simple moving average of $2.68. Gossamer Bio has a 52-week low of $0.76 and a 52-week high of $3.87. The firm has a market capitalization of $502.27 million, a PE ratio of -3.14 and a beta of 1.93.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company's lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.